Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best biotech penny stocks to buy right now. On July 15, Goldman Sachs downgraded Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to Sell from Neutral, bringing the price target down to $1 from $8.

Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple

A medical staff in white coats monitoring the progress of cancer immunotherapy trials.

The firm told investors in a research note that the slower-than-expected launch of Iovance Biotherapeutics, Inc.’s (NASDAQ:IOVA) lead drug Amtagvi in second-line melanoma is the primary reason behind the downgrade.

It added that a physician survey and key opinion leader discussions show underutilization of Amtagvi because of logistical and operational complexities and a limited eligible patient population.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a biopharmaceutical company that develops and commercializes cell therapies as novel cancer immunotherapy products. Its lead product candidate is LN-144, an autologous adoptive cell therapy for metastatic melanoma.

While we acknowledge the potential of IOVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IOVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.